Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

por Guglielmelli, P, Rotunno, G, Fanelli, T, Pacilli, A, Brogi, G, Calabresi, L, Pancrazzi, A, Vannucchi, A M
Publicado 2015

Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.

por Di Massimo, A. M., Di Loreto, M., Pacilli, A., Raucci, G., D'Alatri, L., Mele, A., Bolognesi, A., Polito, L., Stirpe, F., De Santis, R.
Publicado 1997

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

por Vannucchi, A M, Rotunno, G, Bartalucci, N, Raugei, G, Carrai, V, Balliu, M, Mannarelli, C, Pacilli, A, Calabresi, L, Fjerza, R, Pieri, L, Bosi, A, Manfredini, R, Guglielmelli, P
Publicado 2014